[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurotrophic-keratopathy-stage-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurotrophic-keratopathy-stage-1":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100631568","phase-4-effect-of-acoltremon-ophthalmic-solution-0003-on-signs-and-symptoms-of-ocular-surface-disease-in-stage-i-neurotrophic-keratopathy-patients-with-tear-deficiency-100631568",false,"NCT07502378","Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency","Inclusion Criteria:\n\n* Neurotrophic Keratopathy stage 1 diagnosis based on the following: Presence of 3+ fluorescein staining in central cornea and decreased corneal sensation (Cochet-Bonnet less than 4cm in the central cornea)\n* Baseline unanesthetized Schirmer's test ≤ 10 mm\n* Females of childbearing potential must have a negative pregnancy test.\n* Best corrected distance visual acuity (BCDVA), using corrective lenses, if necessary, in the study eye of at least +1.0 Log MAR (Snellen \\\u003C20\u002F200).\n\nExclusion Criteria:\n\n* Evidence of any active ocular infection or any intraocular inflammation.\n* Evidence of any persistent epithelial defect\u002Fulcer or any corneal scar\u002Fcorneal edema.\n* Presence of any other ocular conditions that require topical medications during the treatment phase.\n* History of severe systemic allergies or severe ocular allergies.\n* Inability to suspend topical medications 8 days prior to the starting date and artificial tears 2 hours prior to the first study visit and remain off for the duration of the study.\n* History of any ocular surgery within three months before study visit 1.\n* Ocular surgery expected during the duration of the study.\n* Use of refractive\u002Ftherapeutic contact lenses during the study period.\n* Female subjects who are pregnant\u002Fhave a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period.\n* Drug addiction\u002Falcohol abuse.\n* Participation in another clinical trial concurrently","ALL","18 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"PHASE4","STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.",[25,26],"Ocular Surface Disease","Neurotrophic Keratopathy Stage 1",[25],"RECRUITING","2026-03-25",{"date":31,"type":32},"2026-03-31","ACTUAL",{"date":34,"type":19},"2026-03-27",{"date":36,"type":19},"2027-08-31",{"name":38,"class":39},"University of South Florida","OTHER"]